Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?

[1]  R. D'amico,et al.  Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study , 2004, Circulation.

[2]  G. Berry,et al.  Emboli capture using the Embol-X intraaortic filter in cardiac surgery: a multicentered randomized trial of 1,289 patients. , 2003, The Annals of thoracic surgery.

[3]  K. Schechtman,et al.  The Importance of Prior Stroke for the Adjusted Risk of Neurologic Injury after Cardiac Surgery for Women and Men , 2003, Anesthesiology.

[4]  J. Hammon,et al.  Effectiveness of the Cobra aortic catheter for dual-temperature management during adult cardiac surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[5]  G. Lip,et al.  Valvar heart disease and prosthetic heart valves , 2002, BMJ : British Medical Journal.

[6]  S F Murphy,et al.  Risk factors for early or delayed stroke after cardiac surgery. , 1999, Circulation.

[7]  J. Elefteriades,et al.  Anticoagulation is unnecessary after biological aortic valve replacement. , 1998, Circulation.

[8]  E. Antman,et al.  Guidelines for the management of patients with valvular heart disease: executive summary , 1998, Circulation.

[9]  R. Hall,et al.  Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. , 1995, European heart journal.

[10]  J. Babin-Ebell,et al.  Aortic Bioprosthesis Without Early Anticoagulation-Risk of Thromboembolism , 1995, The Thoracic and cardiovascular surgeon.

[11]  A. Carpentier,et al.  Carpentier-Edwards pericardial bioprosthesis in aortic position: long-term follow-up 1980 to 1994. , 1995, The Annals of thoracic surgery.

[12]  V. Fuster,et al.  High risk of thromboemboli early after bioprosthetic cardiac valve replacement. , 1995, Journal of the American College of Cardiology.

[13]  H. Schultheiss,et al.  Intracardiac thrombosis: patient-related and device-related factors. , 1995, The Journal of heart valve disease.

[14]  J. Jamart,et al.  Mitral valve Carpentier-Edwards bioprosthetic replacement, thromboembolism, and anticoagulants. , 1993, The Annals of thoracic surgery.

[15]  R. Hall,et al.  Guidelines for prevention of thromboembolic events in valvular heart disease. Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology. , 1993, The Journal of heart valve disease.

[16]  J. Alpert,et al.  Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. , 1992, Chest.

[17]  J. Hirsh,et al.  RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT , 1988, The Lancet.

[18]  D. Tweedle.  INTRAVENOUS FAT , 1976, The Lancet.

[19]  T. Orszulak,et al.  Profound reduction in brain embolization using an endoaortic baffle during bypass in swine. , 2002, The Annals of thoracic surgery.

[20]  J. Alpert,et al.  Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. , 2001, Chest.

[21]  D. Faxon,et al.  Guidelines for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease) , 1998 .